Every peptide in this library checked against the FDA drug shortage database, once a day. This is the list that decides whether compounding a copy of a drug is lawful — which is why it matters far more than availability alone.
Checked Oct 16, 2026, 07:23 AM CDT · 318 FDA entries scanned · source
FDA has an open shortage record for at least one presentation of each of these.
Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0) Available Ferring ( Reverified 05/01/2026 ) Company Contact Information: 888-337-7464 Presentation
FDA record for this presentation →Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) Available Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) Available Meitheal Pharmaceuticals, Inc. ( Revised 08/27/2026 ) Company Contact Information: 844-824-8426 Presentation
FDA record for this presentation →A manufacturer has stopped making a particular product. The molecule is usually still available in other forms or from other makers — check the presentation, not just the name.
| Peptide | FDA product | Status | Record |
|---|---|---|---|
| Daptomycin | Daptomycin%20Injection | discontinued | FDA → |
| Insulin | Insulin%20Glargine%20Injection Insulin%20Glargine-aglr%20Injection Insulin%20Lispro%20Injection Insulin%20Lispro%20Protamine%20and%20Insulin%20Lispro%20Injection Insulin%20Lispro-aabc%20Injection | discontinued | FDA → |
| Semaglutide | Semaglutide%20Tablet | discontinued | FDA → |
| Somatropin (recombinant hGH) | Somatropin%20Injection | discontinued | FDA → |
| Vancomycin | Vancomycin%20Hydrochloride%20Injection | discontinued | FDA → |
The other 35 FDA-regulated peptides in this library. Absence from the shortage database means FDA is not tracking a supply problem — it does not guarantee your pharmacy has stock.
47 compounds in this library are not FDA-approved drug products — research chemicals, cosmetic ingredients and compounds still in trials. FDA does not track their supply, so they have no shortage status in either direction. A research peptide is never "in shortage" and never "in good supply"; it is outside the system that produces this page.
Under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy or outsourcing facility may not make a copy of a commercially available approved drug. There is an exception: a drug on FDA's shortage list may be compounded while the shortage lasts.
That single provision explains most of what people have seen in this market. When semaglutide and tirzepatide were listed as in shortage, compounded versions were widely and lawfully sold. When FDA declared those shortages resolved, the exception closed and that supply became unlawful — the molecule had not changed, the list had.
What this means in practice. If a compound is not on the list above, a seller offering a "compounded" version of it is, in most circumstances, selling something they are not permitted to make. That is a strong signal about how the rest of their operation is run — and it is checkable, here or at the FDA source, before anyone spends anything.
A shortage says nothing about whether a drug works or whether it is safe. It is a supply fact — manufacturing problems, demand surges, discontinued lines, raw material delays. A 5-rated drug and a poorly evidenced one appear on this list on exactly the same terms.
A scheduled job reads the FDA database once a day, matches every entry against the 89 monographs here by active ingredient and brand name, and fetches the FDA record for each match. Nothing is typed in by hand and nothing is fetched while you are reading.
If the scan fails, or if the FDA page changes shape enough that the parse returns implausibly few entries, the previous snapshot is kept and the warning at the top of this page appears. The one thing this page will never do is show you an empty table and let you conclude that nothing is in shortage.
Source: FDA Drug Shortages Database, a public U.S. Government resource. pepteyes.com is not affiliated with or endorsed by the FDA. Where this page and the FDA database disagree, the FDA is right.